151414-46-9

Basic information

• Product Name: 3,5-Difluoro-2-nitrophenol
• Synonyms: 3,5-DIFLUORO-2-NITROPHENOL;2,4-Difluoro-6-hydroxynitrobenzene
• CAS NO: 151414-46-9
• Molecular Formula: C₆H₃F₂NO₃
• Molecular Weight: 175.09
• Mol File: 151414-46-9.mol
• Article Data: 12

Chemical Properties

• Melting Point: 46.1-46.5
• Boiling Point: 241.6 °C at 760 mmHg
• Flash Point: 99.9 °C
• Appearance: /
• Density: 1.619 g/cm³
• Vapor Pressure: 0.0229mmHg at 25°C
• Refractive Index: 1.554
• Storage Temp.: Inert atmosphere,Room Temperature
• PKA: 2.60±0.20(Predicted)
• CAS DataBase Reference: 3,5-Difluoro-2-nitrophenol(CAS DataBase Reference)
• NIST Chemistry Reference: 3,5-Difluoro-2-nitrophenol(151414-46-9)
• EPA Substance Registry System: 3,5-Difluoro-2-nitrophenol(151414-46-9)

Safety Data

• Hazard Codes: Xi,T
• Statements: 25
• Safety Statements: 45
• Hazardous Substances Data: 151414-46-9(Hazardous Substances Data)

Usage

General Description

3,5-Difluoro-2-nitrophenol is a chemical compound with the molecular formula C6H3F2NO3. It is a pale yellow solid that is soluble in water and organic solvents. 3,5-Difluoro-2-nitrophenol is used in organic synthesis as a building block for the preparation of various pharmaceuticals and agrochemicals. It is also used as a reagent in the production of dyes and pigments. 3,5-Difluoro-2-nitrophenol is considered to be toxic and harmful if ingested, inhaled, or in contact with the skin. It is important to handle this compound with care and follow proper safety precautions when working with it.

InChI:InChI=1/C6H3F2NO3/c7-3-1-4(8)6(9(11)12)5(10)2-3/h1-2,10H

Upstream product

• 315-14-0 1,3,5-trifluoro-2-nitrobenzene 
• 771-69-7 2,3,4-trifluoronitrobenzene 
• 62018-65-9 chloroform ethyl acetate 
• 2713-34-0 3,5-difluorophenol 
• 372-38-3 1,3,5-trifluorobenzene 
• 124-41-4 sodium methylate 

Downstream Products

• 1159795-35-3 2-bromo-1-(5-fluoro-3-methoxy-2-nitrophenyl)-4-methyl-1H-imidazole 
• 1226803-99-1 8-fluoro-6-methoxy-1-(2-methoxyphenyl)-3-methylimidazo[5,1-c][1,2,4]benzotriazine 
• 1226803-97-9 8-fluoro-6-methoxy-1-(3-methoxyphenyl)-3-methylimidazo[5,1-c][1,2,4]benzotriazine 
• 1226804-27-8 8-fluoro-1-(3-fluoro-2-methylphenyl)-6-methoxy-3-methylimidazo[5,1-c][1,2,4]benzotriazine 
• 163733-98-0 2-amino-3,5-difluorophenol 

Relevant articles and documents

Novel triazines as potent and selective phosphodiesterase 10A inhibitors

The identification of highly potent and orally active triazines for the inhibition of PDE10A is reported. The new analogs exhibit low-nanomolar potency for PDE10A, demonstrate high selectivity against all other members of the PDE family, and show desired drug-like properties. Employing structure-based drug design approaches, we investigated the selectivity of PDE10A inhibitors against other known PDE isoforms, by methodically exploring the various sub-regions of the PDE10A ligand binding pocket. A systematic assessment of the ADME and pharmacokinetic properties of the newly synthesized compounds has led to the design of drug-like candidates with good brain permeability and desirable drug kinetics (t1/2, bioavailability, clearance). Compound 66 was highly potent for PDE10A (IC50 = 1.4 nM), demonstrated high selectivity (>200×) for the other PDEs, and was efficacious in animal models of psychoses; reversal of MK-801 induced hyperactivity (MED = 0.1 mg/kg) and conditioned avoidance responding (CAR; ID50 = 0.2 mg/kg).

NOVEL MEK INHIBITORS, USEFUL IN THE TREATMENT OF DISEASES

The invention pertains to compound of Formula (I) wherein X, Y, Z, R1, R2, R3, R4, A and A' are as described hereinabove. Formula (I) and (II) compounds can be used in pharmaceutical compositions, useful for the treatment of diseases

1-ORTHOFLUOROPHENYL SUBSTITUTED 1, 2 , 5-THIAZOLIDINEDIONE DERIVATIVES AS PTP-AS INHIBITORS

Compounds of the formula (I) are inhibitors of protein tyrosine phosphatases (PTPases) and, thus, may be employed for the treatment of conditions mediated by PTPase activity. The compounds of the present invention may also be employed as inhibitors of other enzymes characterized with a phosphotyrosine binding region such as the SH2 domain. Accordingly, the compounds of formula (I) may be employed for prevention and/or treatment of insulin resistance associated with obesity, glucose intolerance, diabetes mellitus, hypertension and ischemic diseases of the large and small blood vessels, conditions that accompany type-2 diabetes, including hyperlipidemia, hypertriglyceridemia, atherosclerosis, vascular restenosis, irritable bowel syndrome, pancreatitis, adipose cell tumors and carcinomas such as liposarcoma, dyslipidemia, and other disorders where insulin resistance is indicated. In addition, the compounds of the present invention may be employed to treat and/or prevent cancer, osteoporosis, neurodegenerative and infectious diseases, and diseases involving inflammation and the immune system.